RNA binding motif protein 15BGenealiases: HUMAGCGB · HsOTT3 · OTT3
Q-omics provides the consensus-scored RBM15B profile across patient tissues and cancer cell-line models. RBM15B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RBM15B is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, RBM15B RNA expression shows 19,388 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, LIHC, and ACC as cancer lineages where RBM15B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM15B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM15B survival associations across molecular data types. RBM15B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM15B RNA expression–survival associations across cancer types. High RBM15B expression shows unfavorable associations in ACC and LIHC, but favorable associations in UVM, BRCA, KIRC and SCLC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RBM15B RNA expression.
This table summarizes RBM15B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RBM15B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM15B shows higher tumor expression in LIHC, KIRP, COAD, CHOL, STAD and LUAD. The LIHC box plot shows higher RBM15B RNA expression in tumor versus normal tissue (log2 FC = +1.199, t-test p < 0.001).
This table shows molecular features associated with RBM15B in patient tissues and cancer cell lines. In patient samples, RBM15B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM15B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
